Can a monthly injection stop MS in its tracks? new study aims to find out

NCT ID NCT05084638

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a monthly injection of ofatumumab in 180 people with very early relapsing-remitting multiple sclerosis (MS). The goal was to see if the drug could stop all signs of disease activity—like relapses, disability worsening, and new brain lesions—over 18 months. Researchers also compared these patients to healthy volunteers to see if treatment could make their health measures similar to people without MS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSE REMITTING MULTIPLE SCLEROSIS

Contacts and locations

Locations

Arizona Neuroscience Research LLC

Phoenix, Arizona, 85032, United States
Barrow Neurological Clinics at St Josephs Hospital and MC

Phoenix, Arizona, 85013, United States
Caribbean Center for Clinical Research, Inc

Guaynabo, 00968, Puerto Rico
Emerald Coast Neurology

Pensacola, Florida, 32514, United States
Evergreen Health Multiple Sclerosis Center

Kirkland, Washington, 98034, United States
First Choice Neurology

Boca Raton, Florida, 33486, United States
Henry Ford Hospital

Detroit, Michigan, 48202-2689, United States
Keck School of Medicine

Los Angeles, California, 90033, United States
Lonestar Neurology of San Antonio

San Antonio, Texas, 78258, United States
Lundquist Inst BioMed at Harbor

Torrance, California, 90509-2910, United States
MD First Research

Chandler, Arizona, 85226, United States
MedStar Health

Washington D.C., District of Columbia, 20007, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
MultiCare Neuroscience Center of Washington

Tacoma, Washington, 98405, United States
Multiple Sclerosis Center of Excellence of OMRF

Oklahoma City, Oklahoma, 73104, United States
Neurology Associates PA

Maitland, Florida, 32751, United States
Neurology Diagnostics Inc

Dayton, Ohio, 45408, United States
Neurology of Central FL Res Ctr

Altamonte Springs, Florida, 32714, United States
Neuroscience Institute at Hackensack

Hackensack, New Jersey, 07601, United States
Ochsner Cancer Institute

New Orleans, Louisiana, 70121, United States
Orlando Health Clinical Trials

Orlando, Florida, 32806, United States
Regina Berkovich MD PhD Inc

West Hollywood, California, 90048, United States
Renown Institute for Neurosciences

Reno, Nevada, 89521, United States
Shepherd Center

Atlanta, Georgia, 30309, United States
Sibyl Wray MD Neurology PC

Knoxville, Tennessee, 37922, United States
Tallahassee Neurological Clinic

Tallahassee, Florida, 32308, United States
Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107-5098, United States
UC Health Neuroscience Ctr

Aurora, Colorado, 80045, United States
UT Health Science Center

Houston, Texas, 77030, United States
Univ of Texas Southwest Med Center

Dallas, Texas, 75390-9034, United States
University Of South Florida

Tampa, Florida, 33612, United States
University of Florida

Gainesville, Florida, 32610, United States
University of Massachusetts Medical School

Worcester, Massachusetts, 01655, United States
University of New Mexico

Albuquerque, New Mexico, 87131-0001, United States
Velocity Clinical Research

Raleigh, North Carolina, 27607, United States
West Virginia University Hospital

Morgantown, West Virginia, 26506, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.